ABSTRACT
INTRODUCTION Implantable drug compositions have been developed that deliver two or more compounds in a single dose and provide controlled delivery of such compounds. In particular, in U.S. Patent 6,051,576, we have described pharmaceutical compounds covalently linking two or more drug compounds (parent drugs) to form a single compound that has relatively low solubility in biological fluids, and that is quickly hydrolyzed to form the parent compounds when dissolved at or near pH 7.4 (1). The potential use of codrugs, or mutual prodrugs, for synergistic biological effect has been described in several therapeutic categories including antimicrobials (2,3), analgesia (4,5), inflammation (6,7), HIV infection (8), oncology (9), alcoholism (10), and ophthalmology (11-14).
